This trial is active, not recruiting.

Conditions glioblastoma multiforme, recurrent tumor
Treatment dnx2401 and temozolomide
Phase phase 1
Sponsor Clinica Universidad de Navarra, Universidad de Navarra
Collaborator DNAtrix, Inc.
Start date September 2013
End date December 2015
Trial size 31 participants
Trial identifier NCT01956734, D24GBM EudraCT: 2011-005935-21


Phase I trial, unicentric, uncontrolled. Intratumoral injection or intramural (into the resected tumor cavity) of DNX2401 into brain tissue will be followed by up to two 28 - day cycles of oral temozolomide (TMZ) in schedule of 7 days on/7 days off to evaluate safety of the combination. Completion of two full cycles of TMZ will be dependent upon tolerance and toxicity.

The rationale in using the virus with chemotherapy begins with the lessons learned in many clinical trials in glioblastoma (GBM) about both the great difficulty of treating this disease with monotherapy and the limitations of the therapeutic virus. The best clinical results in recent years have been achieved with combinations of multiple therapeutics efforts, including, maximum resection and chemotherapy, immunotherapy and targeted therapies.

There are very strong preclinical data about the synergy of DNX-2401 and TMZ proposed in our trial design. The dose-dense schemes of TMZ like the one we will use, have been developed with the aim to saturate o6-methylguanine-DNA-methyltransferase (MGMT). The published results to date have shown reasonable toxicity albeit with modest efficacy' these schemes are now in phase III trials. In addition, autophagy triggered by TMZ could help viral replication in the tumor cells 11.

The last argument in favor of this virus + TMZ combination is the proved efficacy in killing GBM tumor stem cells. In vitro and animals models have shown this combination is much more effective that any of the treatments alone against GBM stem cells and the tumors derived from them.

United States No locations recruiting
Other Countries No locations recruiting

Study Design

Endpoint classification safety study
Intervention model single group assignment
Masking open label
Primary purpose treatment
DNX2401: Virus injection in the brain parenchyma. Total dose will be 3x1010 vp suspended in 1 ml for all cases. Temozolomide: 14 (window 14-28 days) days after the virus injection, patients will begin therapy with temozolomide in a dose of 150mg/m2 in days 1-7 and 15 -21 of a 28 days cycle, (dose dense scheme 7 days on, 7 days off), until a maximum of 2 x 28 days cycles in absence of toxicity.
dnx2401 and temozolomide
Virus injection in the brain parenchyma after pathology confirmation of recurrent glioblastoma. Temozolomide oral 14 days after virus injection.

Primary Outcomes

Number of participans with adverse events
time frame: 3 months

Secondary Outcomes

Efficacy of the combination: PFS6 and OS12
time frame: 12 months
Tumor response
time frame: 12 months
Quality of life
time frame: 18 months
Biological response
time frame: 3 months

Eligibility Criteria

Male or female participants from 18 years up to 75 years old.

Inclusion criteria: - Patients willing and able to give informed consent and willing to comply with all the protocol procedures. - Patient must be, in the investigator opinion, able to comply with all the protocol procedures. - Age 18-75 years. - Negative pregnant test in case of fertile women. - Patient diagnosed GBM in first recurrence after radiotherapy and TMZ. Must have completed at least radiotherapy and one TMZ cycle afterwards. - Intraoperative histological verification of recurrence is needed to confirm inclusion. - Karnofsky Performance Status ≥ 70 before inclusion - Lesion considered by the investigator to be resectable or accessible for stereotactic biopsy. Lesion location will allow injection without entrance of virus in the ventricular system. - Last TMZ cycle must have been finished at least 4 weeks before entry in the study. - Must have adequate renal, bone marrow and liver function. Exclusion criteria: - Severe infections or intercurrent medical conditions including, but not limited to, severe renal, hepatic, heart or bone marrow failure, that, on investigator´s criteria, do not allow the inclusion. - Participation on another clinical trial in the previous 30 days. - Previous hypersensitivity to temozolomide or any associated components. Previous serious toxicity to temozolomide. - Subjects with immunodeficiency, autoimmune conditions or active hepatitis. - Any medical or psychological condition that might interfere with the subject's ability to participate or give informed consent. - Tumor with multiple locations, unless all the lesions are considered resectable, or all the lesions except one can be resected, and the last one can be injected; diffuse subependymal spreading or location that would need injection through ventricle. - Current diagnosis of other cancer except in situ cervical cancer, basal or squamous cell carcinoma of the skin. Patients with a history of another cancer remain eligible if they are cancer free for at least three years. - Pregnant or breast-feeding females will be excluded, due to the risk for the fetal development of a recombinant virus containing genes related to cellular growth and differentiation. - Severe bone marrow hypoplasia. - Aspartate aminotransferase (AST) or Alanine aminotransferase (ALT) > 3 times over normal laboratory level.

Additional Information

Official title Phase I Trial of Combination of DNX-2401 (Formerly Named Delta-24-RGD) Oncolytic Adenovirus With a Short Course of Temozolomide for Treatment of Glioblastoma at First Recurrent
Principal investigator Sonia Tejada, MD, PhD
Description DNX2401 will be injected after stereotactic biopsy reveals intraoperative pathology confirming the presence of recurrent glioblastoma. The injection will be either intratumoral or intramural with injections throughout the post-resection cavity.
Trial information was received from ClinicalTrials.gov and was last updated in November 2015.
Information provided to ClinicalTrials.gov by Clinica Universidad de Navarra, Universidad de Navarra.